Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Baricitinib

Herpes zoster, rebound effect in the form of flare of granuloma annulare and off-label use: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Jadoul A, et al. JAK1/2 pathway-specific treatment of disseminated granuloma annulare with baricitinib. Journal of the European Academy of Dermatology and Venereology 37: e1006-e1008, No. 8, Aug 2023. Available from: URL: http://doi.org/10.1111/jdv.19073 Jadoul A, et al. JAK1/2 pathway-specific treatment of disseminated granuloma annulare with baricitinib. Journal of the European Academy of Dermatology and Venereology 37: e1006-e1008, No. 8, Aug 2023. Available from: URL: http://​doi.​org/​10.​1111/​jdv.​19073
Metadaten
Titel
Baricitinib
Herpes zoster, rebound effect in the form of flare of granuloma annulare and off-label use: case report
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-47144-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Rituximab

Case report

Upadacitinib